Actively Recruiting

FEMALE
ID02892877

The French National Reference Centre of Gestational Trophoblastic Disease

Led by Hospices Civils de Lyon · Updated on 2016-09-08

25500

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are working through the French National Reference Centre of Gestational Trophoblastic Disease to improve how this rare group of pregnancy-related tumors is managed across France. Since 1999, the center has registered and monitored women diagnosed with gestational trophoblastic disease (GTD), including molar pregnancies and related neoplasias, by collaborating with local doctors and specialists. This observational study aims to support patient care through expert review and coordinated follow-up while tracking how diagnoses agree between local and central pathologists. The center operates with a multidisciplinary approach that keeps patients primarily under the care of their local gynecologists. When a molar pregnancy is diagnosed, the local doctor contacts the center to report the case and obtain guidance. The center sends consent forms and information to patients and physicians, and arranges for expert pathologists to review pathology slides centrally. Patients undergo regular blood tests to monitor hCG levels at local labs, with results reviewed weekly by the center to guide ongoing care. If abnormal hCG patterns or more serious trophoblastic tumors are suspected, further imaging and evaluation are conducted to determine appropriate treatment plans. Participants remain primarily under their local physician's care but are closely followed by the center through regular communication and data collection. The study collects weekly hCG data to track disease progression and treatment response, sending updates to physicians at key milestones. The main outcome measured is whether local and central pathologists agree on diagnoses within 18 months. This coordinated approach aims to enhance diagnosis accuracy, treatment decisions, and fertility preservation for women with GTD. Women can expect ongoing monitoring and timely specialist input throughout their care journey.

CONDITIONS

Brief Title

The French National Reference Centre of GTD

Who Can Participate

FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with a histologically confirmed trophoblastic disease
  • Patients diagnosed with gestational trophoblastic neoplasia based on abnormal hCG levels
Not Eligible

You will not qualify if you...

  • none

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Surveillance

Duration - Up to 18 months

Participants with gestational trophoblastic diseases are observed and monitored over time.

Trial Site Locations

Total: 1 location

1

Centre des Maladies Trophoblastiques Centre Hospitalier Lyon Sud-Bâtiment 3B-2ème étage, 165 Chemin du Grand Revoyet

Pierre-Bénite, France, 69495

Actively Recruiting

Loading map...

Research Team

F

François Golfier, Pr

T

Touria Hajri

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

5

Similar Trials

A Feasibility Window Study of Pembrolizumab Prior to Second ...

Gestational Trophoblastic Disease

Actively Recruiting

1 location

Application and Promotion of the Whole-process Management an...

Hydatidiform Mole

Actively Recruiting

14 locations

ASk Questions in GYnecologic Oncology: Randomized Trial of a...

Ovarian Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here